Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder

Abstract

Get full access to this article

View all access options for this article.

References

Yamout

Beaini

Zeineddine

et al . Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder. Mult Scler 2017; 23: 1297–1300.

Kira

JI.

Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?

Mult Scler 2017; 23: 1300–1302.

Jarius

Ruprecht

Kleiter

et al . MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13(1): 280.

Mitsdoerffer

Kuchroo

Korn

Immunology of neuromyelitis optica: A T cell-B cell collaboration. Ann N Y Acad Sci 2013; 1283: 57–66.

Lee

Laemmer

Waschbisch

et al . Neuromyelitis optica presenting with relapses under treatment with natalizumab: A case report. J Med Case Rep 2014; 8: 155.

Yoshii

Moriya

Ohnuki

et al . Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2016; 7: 53–57.

Tsourdi

Gruber

Rauner

et al . Graves’ disease after treatment with alemtuzumab for multiple sclerosis. Hormones 2015; 14(1): 148–153.

Demir

Heckers

Pedreiturria

et al . Low dose fumaric acid esters are effective in a mouse model of spontaneous chronic encephalomyelitis. J Neuroimmunol 2015; 285: 16–21.

Rezk

Ghadiri

et al . Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis. J Immunol 2017; 198(2): 691–698.

10.

Fleischer

Friedrich

Rezk

et al . Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. Mult Scler. Epub ahead of print 1 April 2017. DOI: 10.1177/1352458517703799.

11.

Gold

Kappos

Arnold

et al . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367(12): 1098–1107. Erratum in N Engl J Med 2012; 367(24): 2362.

12.

Fox

Miller

Phillips

et al . Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367(12): 1087–1097. Erratum in N Engl J Med 2012; 367(17): 1673.